The Hemodynamic Response to Prolonged Dobutamine Infusion

Hadassah Medical Center

Status and phase: Unknown; Phase 4

Conditions: Healthy; Heart Failure

Treatments: Drug: 3 hours intravenous dobutamine

Study type: Interventional

Funder types: Other

Identifiers

NCT01042873

0355-09-HMO-CTIL

0355-09-HMO (Other Identifier)

Details and patient eligibility

About

A decrease in the response of beta 1 adrenergic receptors to agonists (desensitization) is thought to play a major role in the pathogenesis of diseases such as congestive heart failure. However, currently, there is no in vivo model that will enable us to measure desensitization of the hemodynamic responses to beta 1 adrenergic receptors in vivo.

Our hypothesis is that constant 3 hours intravenous infusion of the selective beta1 adrenergic receptor agonist dobutamine will result in gradual decline in hemodynamic responses to dobutamine over time.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• healthy subjects

Exclusion criteria

• consumption of any medications during the 2 weeks prior to the study
• history of chest pain or tachycardia

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Intravenous dobutamine

Other group

Description:

3 hours infusion of dobutamine

Treatment:

Drug: 3 hours intravenous dobutamine